Literature DB >> 35814519

Management of Portal Hypertension.

Anand V Kulkarni1, Atoosa Rabiee2, Arpan Mohanty3.   

Abstract

Portal hypertension is the cause of the clinical complications associated with cirrhosis. The primary complications of portal hypertension are ascites, acute variceal bleed, and hepatic encephalopathy. Hepatic venous pressure gradient measurement remains the gold standard test for diagnosing cirrhosis-related portal hypertension. Hepatic venous pressure gradient more than 10 mmHg is associated with an increased risk of complications and is termed clinically significant portal hypertension (CSPH). Clinical, laboratory, and imaging methods can also aid in diagnosing CSPH non-invasively. Recently, deep learning methods have been demonstrated to diagnose CSPH effectively. The management of portal hypertension is always individualized and is dependent on the etiology, the availability of therapies, and the degree of portal hypertension complications. In this review, we discuss the diagnosis and management of cirrhosis-related portal hypertension in detail. Also, we highlight the history of portal hypertension and future research areas in portal hypertension.
© 2022 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACLF, acute-on-chronic liver failure; AKI, acute kidney injury; APRI, AST to platelet ratio; AST, aspartate transaminase; BB, Beta blocker; BRTO, balloon occluded retrograde transvenous obliteration; CKD, chronic kidney disease; CSPH, clinically significant portal hypertension; CT, computed tomography; GFR, glomerular filtration rate; GOV, gastrpoesopahegal varices; HE, hepatic encephalopathy; HRS, hepatorenal syndrome; HVPG, hepatic venous pressure gradient; ICG, indocyanine green; LOLA, l-ornithine l-aspartate; NAFLD, Non-alcoholic fatty liver disease; SBP, spontaneous bacterial peritonitis; SGLT2I, sodium glucose co-transporter 2 inhibitors; SSM, splenic stiffness measurement; TE, transient elastography; TIPS, transjugular intrahepatic portosystemic shunt; VITRO, von Willebrand factor to platelet counts; acute kidney injury; ascites; hemodynamics; history; vasoconstrictors

Year:  2022        PMID: 35814519      PMCID: PMC9257868          DOI: 10.1016/j.jceh.2022.03.002

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  150 in total

1.  Effect of plasma-volume expansion on portal hypertension.

Authors:  J L Boyer; C Chatterjee; F L Iber; A K Basu
Journal:  N Engl J Med       Date:  1966-10-06       Impact factor: 91.245

2.  Empagliflozin Eliminates Refractory Ascites and Hepatic Hydrothorax in a Patient With Primary Biliary Cirrhosis.

Authors:  Georgios N Kalambokis; Ilias Tsiakas; Sebastien Filippas-Ntekuan; Maria Christaki; Grigorios Despotis; Haralampos Milionis
Journal:  Am J Gastroenterol       Date:  2021-03-01       Impact factor: 10.864

Review 3.  Baveno VII - Renewing consensus in portal hypertension.

Authors:  Roberto de Franchis; Jaime Bosch; Guadalupe Garcia-Tsao; Thomas Reiberger; Cristina Ripoll
Journal:  J Hepatol       Date:  2021-12-30       Impact factor: 30.083

4.  Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT.

Authors:  Vipin Gupta; Ramakant Rawat; Anoop Saraya
Journal:  Hepatol Int       Date:  2016-09-13       Impact factor: 6.047

5.  Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival.

Authors:  Amr S Hanafy; Ahmad M Hassaneen
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-12       Impact factor: 2.566

6.  Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.

Authors:  Xin Zhang; Shu-Zhen Wang; Jun-Fu Zheng; Wen-Min Zhao; Peng Li; Chun-Lei Fan; Bing Li; Pei-Ling Dong; Lei Li; Hui-Guo Ding
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

7.  A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding.

Authors:  G-H Lo; H-L Liang; W-C Chen; M-H Chen; K-H Lai; P-I Hsu; C-K Lin; H-H Chan; H-B Pan
Journal:  Endoscopy       Date:  2007-08       Impact factor: 10.093

8.  Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Scott W Biggins; Paulo Angeli; Guadalupe Garcia-Tsao; Pere Ginès; Simon C Ling; Mitra K Nadim; Florence Wong; W Ray Kim
Journal:  Hepatology       Date:  2021-08       Impact factor: 17.425

9.  Diagnostic accuracy of spleen stiffness to evaluate portal hypertension and esophageal varices in chronic liver disease: a systematic review and meta-analysis.

Authors:  Xing Hu; Xiaojie Huang; Jianhua Hou; Lei Ding; Chunling Su; Fankun Meng
Journal:  Eur Radiol       Date:  2020-09-24       Impact factor: 5.315

Review 10.  Diagnostic Accuracy of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex Scores in Predicting the Presence of Esophageal Varices in Liver Cirrhosis: A Systematic Review and Meta-Analysis.

Authors:  Han Deng; Xingshun Qi; Xiaozhong Guo
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.